Prometic announces agreement to commercialize prion capture technology
Due to the changing landscape surrounding prion transmission and the worldwide mounting interest in improving the safety profile of blood-derived therapeutics, both companies believe that this arrangement will allow them to more fully exploit ProMetic’s validated prion capture technology platform.
This Agreement is complementary to ProMetic’s outstanding commercial arrangements regarding the exploitation of its prion capture technology platform, such as those with MacoPharma SA for the commercialization of the P-Capt® prion capture filter and with Octapharma AG for OctaplasLG®, the only commercially available prion-reduced plasma for transfusion.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.